FDA Approves Lilly’s Evista For Breast Cancer
Eli Lilly and Co.’s osteoporosis drug Evista has been approved to reduce risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer, the Indianapolis drugmaker announced today. The U.S. Food and Drug Administration move came after an FDA advisory panel in late July recommended the […]